Last mentioned: Mar 21, 2026
Invenomic Capital Management has fully liquidated its $24.3 million stake in Haemonetics Corporation (HAE) following a period of significant market underperformance. The move signals a strategic shift for the fund as it reallocates capital toward more resilient healthcare and technology holdings.
Invenomic Capital Management has fully liquidated its $24.29 million position in Haemonetics Corporation, signaling a shift away from the underperforming medical device maker. The exit comes as Haemonetics shares have lagged the broader market, dropping 9% over the past year while the fund rotates capital into diversified healthcare and technology plays.
Invenomic Capital Management has fully liquidated its $24.29 million position in Haemonetics Corporation, a leader in blood and plasma management technology. The exit comes as the stock underperformed the broader market by 25% over the past year, signaling a shift in institutional sentiment toward the medical device sector.